Blog Exposure - Wright Medical Group Announces New Product Launches at the American Orthopaedic Foot & Ankle Society
ACCESS Newswire
LONDON, UK / ACCESSWIRE / July 13, 2018 / If you want access to our free research report on Wright Medical Group N.V. (WMGI) ("Wright"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=WMGI as the Company's latest news hit the wire. On July 11, 2018, the Company announced that it will highlight new innovations at the American Orthopaedic Foot & Ankle Society (AOFAS) 2018 Annual Meeting, which is taking place from July 11-14, 2018. The Company will feature its full range of lower extremities and biologic solutions, including the PROstep™ Minimally Invasive Surgery System and AUGMENT® Injectable Bone Graft. Register today and get access to over 1,000 Free Research Reports by joining our site below:
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Wright Medical Group most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
Wright stated the PROstep™ system, which is specifically designed for foot and ankle surgery, provides a minimally invasive, procedurally integrated solution that features specifically designed implants and instrumentation for percutaneous surgery of the foot.
Wright noted that the PROstep™ System can be used to treat a variety of forefoot and hindfoot pathologies, including one of the most common, Hallux Valgus, commonly known as bunions, which is a painful foot deformity that is prevalent in approximately 23% in adults aged 18 to 65 years, and 35.7% in elderly people aged over 65 years. The Company asserted that compared to a traditional open surgery, the PROstep™ System has demonstrated that it can help patients to be back on their feet faster, with less pain and an improved cosmetic result.
Concerning its AUGMENT® Injectable, Wright stated that it is the first clinically proven injectable protein therapeutic to come to the US orthopedic market offering an alternative to autograft in ankle and/or hindfoot fusion procedures, which translates into an estimated market opportunity of approximately $300 million in the US.
Other Launches
Wright also announced that, at the AOFAS, it will also display the SALVATION™ 2 Limb Reconstruction System, the first comprehensive product solution design to address limb salvage procedures in neuropathic patients. The external fixation system provides preassembled components, patient positioning tools, and reproducible wire placement guides to streamline application and eliminate surgical steps.
Wright will also display INVISION™ Total Ankle Revision System with PROPHECY Preoperative Navigation. The INVISION Total Ankle Revision System helps surgeons re-build bone lost through previous surgeries and provides modularity to help restore natural joint height. Wright stated that the launch of INVISION with PROPHECY will be an important addition to its total ankle portfolio.
Additionally, Wright also announced the achievement of a clinical milestone, which is surpassing 30,000 total ankle replacement (TAR) procedures globally since 2008.
Upcoming Earnings
On July 11, 2018, Wright announced that it will host a conference call on August 08, 2018, at 3:30 p.m. Central Time to discuss the Company's operating results for the second quarter ended July 01, 2018. The operating results will be released at 3:05 p.m. Central Time on the same day.
About Wright Medical Group N.V.
Wright is a global medical device Company focused on extremities and biologics products. The Company is committed to delivering innovative, value-added solutions improving the quality of life for patients worldwide, and is a recognized leader of surgical solutions for the upper extremity (shoulder, elbow, wrist, and hand); lower extremity (foot and ankle); and biologics markets.
Stock Performance Snapshot
July 12, 2018 - At Thursday's closing bell, Wright Medical Group's stock advanced 1.68%, ending the trading session at $26.10.
Volume traded for the day: 651.92 thousand shares.
Stock performance in the last month - up 5.75%; previous three-month period - up 31.82%; past six-month period - up 8.61%; and year-to-date - up 17.57%
After yesterday's close, Wright Medical Group's market cap was at $2.76 billion.
The stock is part of the Healthcare sector, categorized under the Medical Appliances & Equipment industry. This sector was up 1.3% at the end of the session.
Active-Investors:
Active-Investors (A-I) produces regular sponsoredand non-sponsored reports, articles, stock market blogs, and popular investmentnewsletters covering equities listed on NYSE and NASDAQ and Canadian stocks.A-I has two distinct and independent departments. One department producesnon-sponsored analyst certified content generally in the form of pressreleases, articles and reports covering equities listed on NYSE and NASDAQ andthe other produces sponsored content (in most cases not reviewed by aregistered analyst), which typically consists of compensated investmentnewsletters, articles and reports covering listed stocks and micro-caps. Suchsponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly orindirectly; for producing or publishing this document.
PRESS RELEASEPROCEDURES:
The non-sponsored content contained herein has beenprepared by a writer (the "Author") and is fact checked and reviewedby a third-party research service company (the "Reviewer")represented by a credentialed financial analyst [for further information onanalyst credentials, please email info@active-investors.com.Rohit Tuli, a CFA® charterholder (the"Sponsor"), provides necessary guidance in preparing the documenttemplates. The Reviewer has reviewed and revised the content, as necessary,based on publicly available information which is believed to be reliable.Content is researched, written and reviewed on a reasonable-effort basis. TheReviewer has not performed any independent investigations or forensic audits tovalidate the information herein. The Reviewer has only independently reviewedthe information provided by the Author according to the procedures outlined byA-I. A-I is not entitled to veto or interfere in the application of suchprocedures by the third-party research service company to the articles,documents or reports, as the case may be. Unless otherwise noted, any contentoutside of this document has no association with the Author or the Reviewer inany way.
NO WARRANTY
A-I, the Author, and the Reviewer are notresponsible for any error which may be occasioned at the time of printing ofthis document or any error, mistake or shortcoming. No liability is acceptedwhatsoever for any direct, indirect or consequential loss arising from the useof this document. A-I, the Author, and the Reviewer expressly disclaim anyfiduciary responsibility or liability for any consequences, financial orotherwise arising from any reliance placed on the information in this document.Additionally, A-I, the Author, and the Reviewer do not (1) guarantee theaccuracy, timeliness, completeness or correct sequencing of the information, or(2) warrant any results from use of the information. The included informationis subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering,recommendation, or a solicitation of an offer to buy or sell the securitiesmentioned or discussed, and is to be used for informational purposes only.Please read all associated disclosures and disclaimers in full beforeinvesting. Neither A-I nor any party affiliated with us is a registeredinvestment adviser or broker-dealer with any agency or in any jurisdictionwhatsoever. To download our report(s), read our disclosures, or for moreinformation, visit http://active-investors.com/legal-disclaimer/.
CONTACT
For any questions, inquiries, or comments reach outto us directly. If you're a company we are covering andwish to no longer feature on our coverage list contact us via email and/orphone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@active-investors.com Phone number: 73 29 92 6381 OfficeAddress: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, WilayahPersekutuan Kuala Lumpur, Malaysia
